Hypokalaemia and peritoneal dialysis-related peritonitis: Association, risk factors and outcomes

Welcome to AudioScholar. Today we're covering Hypokalaemia and peritoneal dialysis-related peritonitis: Association, risk factors and outcomes, by Kalla S and colleagues, published in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis.

For any clinician managing patients on peritoneal dialysis, or PD, peritonitis remains a constant concern. It’s the most common serious complication of the therapy, frequently leading to hospitalization, catheter removal, a permanent switch to hemodialysis, and in some cases, death. A key goal in PD care is to identify modifiable risk factors that could help prevent these infections. One such potential factor is hypokalemia.

Low serum potassium is relatively common in PD patients, partly because standard dialysate contains no potassium, leading to steady losses. This can be compounded by dietary restrictions or the use of diuretics. The proposed link to peritonitis is biologically plausible: hypokalemia can impair intestinal motility, leading to constipation and bacterial overgrowth, which may increase the risk of bacterial translocation into the peritoneal cavity. Some large observational studies, like the Peritoneal Dialysis Outcomes and Practice Patterns Study, or PDOPPS, have suggested a strong link. A recent randomized trial from Thailand also found that proactive potassium supplementation reduced peritonitis risk. However, the evidence is not entirely consistent, and the current International Society for Peritoneal Dialysis guidelines offer only a weak suggestion to treat hypokalemia. This new study from Australia aims to further clarify this important clinical question.

To do this, the researchers conducted a single-center, retrospective observational study at the Princess Alexandra Hospital in Brisbane. They included all 486 adult patients who started peritoneal dialysis between January 2013 and December 2022. The primary exposure of interest was hypokalemia, which they defined as a serum potassium level below 3.5 millimoles per liter. To get a stable measure, they primarily used the average serum potassium over the first six months of PD therapy. Based on this average, patients were categorized into three groups: a hypokalemic group with potassium under 3.5, a normokalemic group between 3.5 and 4.5, and a hyperkalemic group with potassium over 4.5. The primary outcome was the time from starting PD to the first episode of peritonitis. The investigators used multivariable Cox proportional hazards models to analyze this relationship, adjusting for a range of potential confounders like age, sex, ethnicity, body mass index, and comorbidities.

So, what did they find? First, in this Australian cohort, significant hypokalemia was not very common. Based on the six-month average, only about 6 percent of patients—that’s 30 individuals—fell into the hypokalemic group. The vast majority, 62 percent, were in the normal range, and 32 percent had average potassium levels above 4.5.

The central finding of the study was that there was no statistically significant association between hypokalemia and the risk of peritonitis. When comparing the hypokalemic group to the reference group with normal potassium, the hazard ratio for time to first peritonitis was 1.14. However, the 95 percent confidence interval was very wide, ranging from 0.67 to 1.95. In plain language, this result is statistically non-significant. The data are consistent with hypokalemia potentially reducing the risk by as much as 33 percent, or increasing it by as much as 95 percent. The study simply couldn't provide a precise estimate. This lack of association held true across different analyses, including when they looked at potassium levels at baseline or as a continuous variable.

While the overall peritonitis rate was numerically highest in the low-potassium group—at 0.79 episodes per patient-year, compared to 0.61 in the normal group—this difference was not statistically significant.

Interestingly, the analysis did identify one strong, significant risk factor for peritonitis: obesity. Patients with a body mass index over 30 had a significantly shorter time to their first peritonitis episode, with a hazard ratio of 1.88. This means their risk was nearly doubled compared to patients with a normal BMI.

Looking at secondary outcomes, there was a suggestion that the type of infection might differ. In the small group of patients with hypokalemia, gram-negative organisms appeared to be responsible for a larger proportion of peritonitis cases compared to the other groups, though again, the small numbers mean this should be interpreted with caution.

Now, how should we weigh these findings in our clinical practice? This study has several strengths. The investigators used detailed, longitudinal data on potassium levels and applied multiple robust statistical methods to test their hypothesis, including competing risk regression.

However, the study also has significant limitations that are crucial for interpretation. First, it's a retrospective study from a single center, which limits its generalizability. More importantly, the number of patients in the key exposure group—those with hypokalemia—was very small, at just 30 patients. This means the study had low statistical power. It may have been unable to detect a true, modest association simply because there weren't enough events in the group of interest. The authors themselves acknowledge this, stating that their "estimates were imprecise," which is reflected in the wide confidence intervals. This raises the possibility of a Type II error, or a false negative result. Finally, as with any observational study, there's a risk of residual confounding from factors that weren't measured, such as residual kidney function, use of medications like proton pump inhibitors, or a history of constipation—all of which could influence peritonitis risk.

So, what is the clinical bottom line? This study did not demonstrate an association between hypokalemia and peritonitis risk in this particular Australian PD cohort. This null finding adds an important piece to a complex and somewhat contradictory body of evidence. It suggests that in a population where sustained hypokalemia is relatively uncommon, it may not be a major driver of peritonitis.

However, because of the study's low statistical power, we should be cautious about concluding that no relationship exists. The result doesn't definitively refute the plausible biological link or the positive findings from other, larger studies. For now, the question remains unsettled. This study reinforces that the association may not be universal and could depend on the patient population and the severity and prevalence of hypokalemia.

Perhaps the most actionable finding from this paper is the strong, independent association between a BMI over 30 and an increased risk of peritonitis. This reinforces the need for meticulous exit-site care and patient education in this high-risk group. Ultimately, while this paper provides a valuable, albeit null, contribution, the definitive role of potassium management in preventing PD peritonitis will likely require larger, multi-center randomized controlled trials.

That's your AudioScholar summary. The full transcript and reference are on the episode page. Until next time.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.